HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion - Regional Media News

HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion - Regional Media News

Oct 19 (Reuters) - Hong Kong-listed Metis TechBio said on Monday it has entered into a collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies. The Chinese biotech will use its proprietary AI-driven drug-delivery platform to [...]

METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies

METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.

Metis TechBio Strikes $1.1 Billion Drug Delivery Deal With Eli Lilly; Details

Metis TechBio has signed a drug delivery research deal with Eli Lilly worth up to $1.1 billion, with payments tied to development milestones and product sales.

METiS TechBio signs $1.1B AI drug-delivery deal with Eli Lilly

METiS TechBio and Eli Lilly will develop tissue-targeted RNA delivery systems in a collaboration carrying up to about $1.1 billion in milestones.